ZYRTEC-D 12 HOUR
LOE Approachingcetirizine hydrochloride and pseudoephedrine hydrochloride
NDAORALTABLET, EXTENDED RELEASE
Approved
Aug 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ZYRTEC-D 12 HOUR (cetirizine hydrochloride and pseudoephedrine hydrochloride) by Aurobindo Pharma. Approved for these symptoms due to hay fever, other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose and 2 more indications. First approved in 2001.
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYRTEC-D 12 HOUR is an oral extended-release combination tablet containing cetirizine hydrochloride (a second-generation H1-receptor antagonist) and pseudoephedrine hydrochloride (a nasal decongestant). It treats symptoms of hay fever and upper respiratory allergies including runny nose, sneezing, itchy/watery eyes, and nasal congestion by reducing nasal passage swelling and temporarily restoring freer breathing.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, suggesting defensive commercial strategies and potential downsizing of dedicated brand teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on ZYRTEC-D 12 HOUR at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.